SGP
SpyGlass Pharma, Inc. Common Stock NASDAQ Listed Jan 8, 2008$28.60
Mkt Cap $956.2M
52w Low $17.06
75.0% of range
52w High $32.44
50d MA $24.30
200d MA $23.77
P/E (TTM)
-17.2x
EV/EBITDA
—
P/B
—
Debt/Equity
—
ROE
—
P/FCF
—
RSI (14)
62.70
ATR (14)
$1.49
Beta
0.00
50d MA
$24.30
200d MA
$23.77
Avg Volume
86.6K
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. Its lead product candidate, Bimatoprost Drug Pad-IOL System (BIM-IOL System), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) for patients who have wither open-angel glaucoma (OAG) or ocular hypertension (OHT). The company was founded in January 2019 by Malik Y. Kahook and Glenn Sussman and is headquartered in Aliso Viejo, CA.
CIK (SEC)
Phone
1 949 535 0588
27061 Aliso Creek Road · Aliso Viejo, CA 92656 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -0.51 | -0.59 | -14.7% | 24.75 | -0.5% | +2.3% | -0.6% | -1.2% | +1.7% | -0.4% | — |
| Jun 25, 2026 | AMC | -0.67 | -0.59 | +11.9% | 18.81 | +0.9% | +12.6% | +2.2% | +2.8% | -12.5% | -1.6% | — |
| May 15, 2026 | AMC | -0.67 | -0.69 | -3.0% | 23.21 | +2.0% | -4.2% | -4.7% | +3.3% | +0.7% | -5.5% | — |
| May 14, 2026 | AMC | -0.67 | -0.69 | -3.0% | 24.27 | -9.8% | -4.4% | -4.2% | -4.7% | +3.3% | +0.7% | — |
| Mar 26, 2026 | AMC | -0.57 | -5.72 | -896.1% | 25.20 | -2.3% | -10.3% | +3.4% | +10.9% | -5.7% | -8.1% | — |
| Dec 3, 2025 | AMC | — | -0.45 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 14 | Raymond James | Initiates | Outperform | $39 | $25.17 | $26.01 | +3.3% | +4.1% | -1.6% | +0.2% | +5.4% | -3.7% |
No insider trades available.
8-K · 2.02
!! High
SpyGlass Pharma, Inc. -- 8-K 2.02: Earnings Results
Aug 6
8-K
Tyra Biosciences, Inc. -- 8-K Filing
Tyra Biosciences appointed a board member with significant biopharmaceutical experience, including prior roles at Blueprint Medicines (acquired by Sanofi) and other therapeutic companies.
Apr 17
8-K
Unknown — 8-K Filing
Blco's phase 1/2 data showing 97% of patients eliminated eye drop dependency suggests strong commercial potential for its implantable device, making the $172.5M IPO attractive for investors seeking ophthalmology innovation exposure.
Mar 26
8-K · 8.01
!! High
SpyGlass Pharma, Inc. -- 8-K 8.01: Material Event / Announcement
SpyGlass Pharma reported positive 12-month clinical data from its Bimatoprost Drug Pad-IOL System Phase 1/2 trial, supporting continued development of this innovative intraocular lens technology for treating glaucoma.
Mar 9
8-K · 5.02
!!! Very High
SpyGlass Pharma, Inc. -- 8-K 5.02: Executive Change
SpyGlass Pharma appointed an executive officer to its board of directors, potentially signaling leadership transition and expanded governance responsibilities for the company.
Feb 13
8-K · 7.01
! Medium
SpyGlass Pharma, Inc. -- 8-K 7.01: Regulation FD Disclosure
SpyGlass Pharma disclosed information channels for material announcements, signaling it will communicate updates through SEC filings, its website, press releases, and public calls.
Feb 9
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Sands Capital Alternatives, Llc | 2,500,012 | $65M | New | Mar 2026 |
| 2 | Blackrock, Inc. | 711,712 | $16M | New | Jun 2026 |
| 3 | Deerfield Management Company, L.p. | 550,000 | $14M | New | Mar 2026 |
| 4 | Jpmorgan Chase & Co | 577,109 | $13M | New | Mar 2026 |
| 5 | Millennium Management Llc | 507,257 | $11M | Added | Jun 2026 |
| 6 | Aberdeen Group Plc | 493,076 | $11M | Added | Jun 2026 |
| 7 | Vanguard Capital Management Llc | 434,423 | $10M | — | Jun 2026 |
| 8 | Franklin Resources Inc | 300,000 | $8M | New | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 75,812 | $2M | Added | Jun 2026 |
| 10 | Alyeska Investment Group, L.p. | 57,000 | $1M | New | Mar 2026 |
| 11 | Td Asset Management Inc | 47,580 | $1M | New | Jun 2026 |
| 12 | Marshall Wace, Llp | 29,348 | $760K | New | Mar 2026 |
| 13 | Bank Of America Corp /de/ | 28,020 | $726K | New | Mar 2026 |
| 14 | Northern Trust Corp | 20,862 | $541K | New | Mar 2026 |
| 15 | Virtus Investment Advisers, Llc | 17,744 | $395K | New | Jun 2026 |
| 16 | Nuveen, Llc | 14,649 | $326K | New | Jun 2026 |
| 17 | Rhumbline Advisers | 11,844 | $264K | New | Jun 2026 |
| 18 | Metlife Investment Management, Llc | 6,986 | $156K | New | Jun 2026 |
| 19 | Citigroup Inc | 5,190 | $116K | New | Jun 2026 |
| 20 | Police & Firemen's Retirement System Of New Jersey | 3,268 | $73K | New | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$956.2M
Enterprise Value
$956.0M
P/E (TTM)
-17.23x
Forward P/E
—
PEG Ratio
—
P/B
—
P/S
—
P/FCF
—
EV/EBITDA
—
Shares Out
33.4M
Financials (TTM)
Revenue
$0
Net Income
-$56.1M
EBITDA
-$58.4M
Free Cash Flow
—
Op Cash Flow
—
EPS Basic
—
EPS Diluted
$-1.66
EPS Forward
—
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
—
Total Liab.
—
Total Equity
—
Cash
—
LT Debt
—
Book Value/Sh
—
Debt/Equity
—
Current Ratio
—
Quick Ratio
—
Returns & Growth
ROE
—
ROA
—
ROIC
—
Rev Growth YoY
—
EPS Growth YoY
—
Price Returns
2W
+6.5%
1M
+10.9%
3M
+57.1%
6M
+5.1%
12M
+8.3%
Technicals
52W High
$32.44
52W Low
$17.06
50d MA
$24.30
200d MA
$23.77
RSI (14)
62.70
ATR (14)
$1.49
Beta
0.00
Avg Volume
87K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Oct 22, 2009
Analyst Price Targets
Consensus
$62.00
High
$62.00
Low
$62.00
Median
$62.00
Data updated apr 27, 2026 1:01am
· Source: financialmodelingprep.com